Kallyope

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kallyope sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 5 completed early-phase tilt upper quartile by trial count

Kallyope: 8 sponsored US clinical trials, 1 recruiting.

Kallyope sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus in Obese, with 1 trials.

Upper-quartile sponsor footprint

Kallyope sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Kallyope pipeline

1 recruiting of 8 indexed (13% open); 5 completed (63%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Type 2 Diabetes Mellitus in Obese (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kallyope: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Kallyope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share KallyopeAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
Kallyope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kallyope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this Kallyope page

8 registered trials is a research-attention snapshot, not an endorsement of Kallyope or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kallyope pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.